ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer (ESTIMABL3)
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
This PHASE3 trial investigates Thyroid Cancer and is currently ongoing. Gustave Roussy, Cancer Campus, Grand Paris leads this study, which shows 8 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Mar 2026 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
Jun 2023 — Jun 2024 [monthly]
Recruiting PHASE3
▶ Show 3 earlier versions
-
Feb 2022 — Jun 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE3
-
Jul 2018 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Gustave Roussy, Cancer Campus, Grand Paris
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Angers, France , Bordeaux, France , Bron, France , Caen, France , Clermont-Ferrand, France , Dijon, France , Haguenau, France , Les Abymes, Guadeloupe , Lille, France , Nîmes, France and 8 more locations